Atai Life delivers results from PCN-101 study
Data supports further exploration of candidate as a rapid-acting anti-depressant for home use
Read More
Tag: Atai Life Sciences
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
